Clinical and anamnestic characteristics of patients with an implanted cardioverter-defibrillator in real clinical practice (data from the Kuzbass register)

Aim      To study the consistency of the practice of management, selection and routing of patients at high risk of sudden cardiac death (SCD) selected for cardioverter-defibrillator implantation (CDI) with current clinical guidelines and to evaluate the quality of subsequent outpatient follow-up and treatment based on a retrospective analysis of clinical amnestic data from the Kuzbass Registry of Patients with CDI.

Material and methods  The study was based on the Registry of Patients with Implanted Cardioverter Defibrillator and included successive data of 28 patients hospitalized to the Kizbass Cardiological Center from 2015 through 2019. Social and clinical amnestic characteristics, indications for CVI, and concomitant drug therapy were analyzed retrospectively. Statistical analyses were performed with the Statistica 10.0 software (Statsoft, USA).

Results Median age of patients was 59 (53; 66) years; 239 (83.6 %) men were included; 29 (10.1%) people were employed, CHI was performed in 182 (63.6 %) patients for prevention of SCC, and for secondary prevention in 104 (36.4 %) patients. 208 (72.7 %) patients were diagnosed with ischemic heart disease (IHD), and 145 (67.9 %) of them underwent myocardial revascularization. Noncoronarogenic diseases were found in 78 (27.3 %) patients, and most of them were diagnosed with dilated cardiomyopathy. All patients had chronic heart failure (CHF); half of them had stage IIA CHF. Median left ventricular ejection fraction was 30 (25; 36,5) % according to echocardiography using the Simpson method. Comorbidity was found in 151 (52.8 %) patients. 128 (44.8%) patients received a triple neurohormonal blockade for CHF treatment; titration to target doses was not performed in any of them. Antiarrhythmics were administered to 150 (52.4 %) patients.

Conclusion      According to the data from the Kuzbass Registry of CVI, the main patient cohort consisted of men of pension age with IHD and CHF. Before CVI, more than a half of them had not received an optimum drug therapy and not all of them had received target lesion revascularization. Creating and analysis of Registries of CHI patients is an effective method for identifying existing problems in patient management before CVI and for optimizing their subsequent follow-up and treatment.

1. Hayashi M, Shimizu W, Albert CM. The Spectrum of Epidemiology Underlying Sudden Cardiac Death. Circulation Research. 2015;116(12):1887–906. DOI: 10.1161/CIRCRESAHA.116.304521

2. Wong CX, Brown A, Lau DH, Chugh SS, Albert CM, Kalman JM et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. Heart, Lung and Circulation. 2019;28(1):6–14. DOI: 10.1016/j.hlc.2018.08.026

3. Link MS. Sudden cardiac death in the young: Epidemiology and overview. Congenital Heart Disease. 2017;12(5):597–9. DOI: 10.1111/chd.12494

4. Okrugin S.A., Lvova A.B., Repin A.N. Prehospital sudden death from acute myocardial infarction in Tomsk (1984 and 2018): what has changed for 34 years. Complex Issues of Cardiovascular Diseases. 2020;9(4):6–11. DOI: 10.17802/2306-1278-2020-9-4-6-11

5. Bokeria L.A., Neminushchiy N.M., Mikhaylichenko S.I. Implantable cardioverter-defibrillators - specific method of preventing of sudden cardiac death: development and standardization. Emergency Cardiology. 2018;2:22–33. DOI: 10.25679/EMERGCARDIOLOGY.2018.18.2.003

6. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF et al. Declining risk of sudden death in heart failure. New England Journal of Medicine. 2017;377(1):41–51. DOI: 10.1056/NEJMoa1609758

7. Ilov N.N., Pal’nikova O.V., Nechepurenko A.A., Tarasov D.G. Patients at high risk of sudden cardiac death: life after implantation of a cardioverter-defibrillator (single-center observational study). Clinical and Experimental Surgery. 2018;6(3):98–106. DOI: 10.24411/2308-1198-2018-13011

8. Revishvili A.Sh., Neminushchy N.M. Current implantable cardioverter-defibrillator therapy: progress and standardization. Bulletin of arrhythmology. 2017;87:33–41.

9. Bokeria L.A., Neminushchiy N.M., Mikhaylichenko S.I., Novichkov S.A., Achkasov E.E. Implantable cardioverter-defibrillators in the prevention of sudden cardiac death. Therapeutic Archive. 2017;89(12):103–9. DOI: 10.17116/terarkh20178912103-109

10. Looi K-L, Sidhu K, Cooper L, Dawson L, Slipper D, Gavin A et al. Long-term outcomes of heart failure patients who received primary prevention implantable cardioverter-defibrillator: An observational study. Journal of Arrhythmia. 2018;34(1):46–54. DOI: 10.1002/joa3.12027

11. Kamaliev M.A., Almukhanova A.B., Bapaeva M., Peremitina A.D. Medical efficiency after implantation of the cardioverter-defibrillator. Vestnik KazNMU. 2018;3:283–4.

12. Lebedeva N.B., Dzhun I.E., Kashtalap V.V., Mamchur S.Е. Register of patients with an implanted cardioverter-defibrillator. Certificate of state registration of a computer program. Reg. № 2020662410 from 13.10.2020. Moscow. 2020.

13. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal. 2015;36(41):2793–867. DOI: 10.1093/eurheartj/ehv316

14. Revishvili A.Sh., Neminushchy N.M., Golitsyn S.P. All-Russian clinical recommendations for controlling the risk of sudden cardiac arrest and sudden cardiac death, prevention and first aid. -M.: GEOTARMedia;2018. - 256 p. ISBN 978-5-9704-4464-1

15. Boytsov S.A., Nikulina N.N., Yakushin S.S., Akinina S.A., Furmenko G.I. Sudden cardiac death in patients with coronary heart disease based on the results of the Russian multicenter epidemiological study of morbidity, mortality, quality of diagnosis and treatment of acute forms of CHD (RESONANCE). Russian Cardiology Journal. 2011;16(2):59–64.

16. Myerburg RJ. Sudden Cardiac Death: Exploring the Limits of Our Knowledge. Journal of Cardiovascular Electrophysiology. 2001;12(3):369–81. DOI: 10.1046/j.1540-8167.2001.00369.x

17. Bogachevskaia S.A., Bogachevskiy A.N. A ten year overview of surgical and interventional arrhythmology in russia. Service peculiar features in the far east. Social Aspects of Population Health. 2017;53(1):2. DOI: 10.21045/2071-5021-2017-53-1-1

18. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A et al. Programming Implantable Cardioverter-Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock: Results from the PROVIDE Study: ICD Programming for Shock Reduction. Journal of Cardiovascular Electrophysiology. 2014;25(1):52–9. DOI: 10.1111/jce.12273

19. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):272–391. DOI: 10.1161/CIR.0000000000000549

20. Barbarash O.L., Karpov Yu.A., Kashtalap V.V., Boshchenko A.A., Ruda M.Ya., Akchurin R.S. et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–50. DOI: 10.15829/1560-4071-2020-4076

21. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

22. Finocchiaro G, Magavern E, Sinagra G, Ashley E, Papadakis M, Tome‐Esteban M et al. Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2017;6(12):e007161. DOI: 10.1161/JAHA.117.007161

23. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research. 2017;121(7):749–70. DOI: 10.1161/CIRCRESAHA.117.311059

24. Poliakova A A., Gudkova A.Yu., Krutikov A.N., Semernin E.N., Kozlenok A.V., Pyko S.A. et al. Нypertrophic cardiomyopathy in the older age group: the effect of cardiometabolic risk factors and rs2290149 and rs10838692 of the MADD gene. Arterial Hypertension. 2018;24(1):29–40. DOI: 10.18705/1607-419X-2018-24-1-29-40

25. Bokeria L.A., Bokeria O.L., Temirbulatova A.Sh. Arrhythmogenic dysplasia/cardiomyopathy of the right ventricle. Annals of Arrhythmology. 2010;7(3):47–56.

26. Calkins H. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy – Three Decades of Progress –. Circulation Journal. 2015;79(5):901–13. DOI: 10.1253/circj.CJ-15-0288

27. Varma N, Epstein AE, Irimpen A, Schweikert R, Love C. Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial. Circulation. 2010;122(4):325–32. DOI: 10.1161/CIRCULATIONAHA.110.937409

28. Guédon-Moreau L, Lacroix D, Sadoul N, Clémenty J, Kouakam C, Hermida J-S et al. Costs of remote monitoring vs. ambulatory followups of implanted cardioverter defibrillators in the randomized ECOST study. EP Europace. 2014;16(8):1181–8. DOI: 10.1093/europace/euu012

29. Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C, Setoguchi S et al. Follow-up of Patients With New Cardiovascular Implantable Electronic Devices: Are Experts’ Recommendations Implemented in Routine Clinical Practice? Circulation: Arrhythmia and Electrophysiology. 2013;6(1):108–16. DOI: 10.1161/CIRCEP.112.974337